ArticleInfection and drug resistance2022
Anti-Interferon-γ Autoantibodies Impair T-Lymphocyte Responses in Patients with
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Characteristics and Outcomes of Anti-interferon Gamma Antibody-Associated Adult Onset Immunodeficiency.Journal of clinical immunology · 2023Pooled it
- Anti-interferon-γ autoantibody-associated adult-onset immunodeficiency with occult immunological abnormalities and sequential intracellular infections: a case report.Frontiers in immunology · 2026Article
- Central nervous system infections in patients with anti-interferon-γ autoantibodies: case series and review of the literature.BMC neurology · 2025Review
- Characteristics of polyclonal anti-interferon-gamma autoantibodies and novel diagnostic strategies: A prospective cohort study of new biomarkers.Journal of translational autoimmunity · 2025Article
- Deepening Understanding of the Clinical Features and Diagnostic Approaches to Anti-Interferon-Gamma Autoantibody Associated Adult-Onset Immunodeficiency in the Last 20 Years: A Case Report and Literature Review.Journal of clinical immunology · 2025Review
- Efficacy of Bortezomib for Treating Anti-Interferon-Gamma Autoantibody-Associated Adult-Onset Immunodeficiency Syndrome.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Case report: Systemic multi-organ involvement in an adult-onset immunodeficiency patient infected withFrontiers in immunology · 2024Article
- The microbial damage and host response framework: lesson learned from pathogenic survival trajectories and immunoinflammatory responses ofFrontiers in immunology · 2024Review
- The detectable anti-interferon-γ autoantibodies in COVID-19 patients may be associated with disease severity.Virology journal · 2023Article
- Case report: Diagnosis ofFrontiers in cellular and infection microbiology · 2023Article
- Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19.Current issues in molecular biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although anti-IFN-γ autoantibodies predispose patients to Methods: Total peripheral blood mononuclear cells (PBMCs) from healthy donors or patients with Results: The M1-reactive CD8 Conclusion: Anti-IFN-γ autoantibodies presence in the serum inhibited CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.